08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
Businesses across a wide range of industries are grappling with how to address the practical and leg...
Read More >
Effective January 2020, New Jersey’s Law Against Discrimination (LAD) will prohibit private sector ...
Read More >
Agreeing with a trial court that the arbitration agreements at issue were both procedurally and subs...
Read More >
With a constantly evolving legal landscape, colleges, universities and independent schools encounter...
Read More >
Many employers strongly prefer arbitration to litigating with their employees in court. Employers of...
Read More >
California is potentially setting the precedent on how “employees” will be defined in the future. ...
Read More >